Literature DB >> 6743021

Replication of mumps virus in murine cells.

M Tsurudome, A Yamada, M Hishiyama, Y Ito.   

Abstract

Mumps virus replication was examined in various culture cells derived from mice. Eight of 16 lymphoid cell lines and 4 of 13 non-lymphoid cell lines supported the replication of Vero cell-adapted Enders strain (EY) of mumps virus. EY strain replicated more efficiently in lymphoid cell lines than in non-lymphoid ones. T cell preference, however, was not observed in this study. The growth kinetics of EY strain in high yield cell lines such as EL-4, L1210 and NS-18 cells were similar to that in Vero cells, while in low yield cell lines such as DK, C243 and 203 GL cells the growth patterns varied respectively. Nineteen kinds of primary culture cells of murine origin all proved not to be susceptible for EY strain, even when spleen cells were stimulated with lectins or allogeneic cells. Seven other strains of mumps virus were examined for their ability to replicate in EL-4, L1210 and L929 cells. Four and 6 strains replicated in EL-4 cells and L1210 cells respectively, although the growth patterns and yields varied in each virus-cell combinations. On the other hand, none of 7 strains showed sufficient replication in L929 cells.

Entities:  

Mesh:

Year:  1984        PMID: 6743021     DOI: 10.1007/BF01309293

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  15 in total

1.  Natural pathogenicity of mumps virus for suckling hamsters on intracerebral inoculation.

Authors:  L KILHAM; J R OVERMAN
Journal:  J Immunol       Date:  1953-02       Impact factor: 5.422

2.  Propagation of mumps virus in suckling mice and in mouse embryo tissue cultures.

Authors:  L KILHAM; H W MURPHY
Journal:  Proc Soc Exp Biol Med       Date:  1952-07

3.  Experimental viral infections of the inner ear. I. Acute infections of the newborn hamster labyrinth.

Authors:  L E Davis; R T Johnson
Journal:  Lab Invest       Date:  1976-04       Impact factor: 5.662

4.  Experimental intraocular infection of guinea pigs with mumps virus.

Authors:  V S BOLIN; J A ANDERSON; G R LEYMASTER
Journal:  Proc Soc Exp Biol Med       Date:  1950-10

5.  T lymphocyte-dependent difference in susceptibility between DDD and C3H mice to mouse hepatitis virus, MHV-3.

Authors:  A Yamada; F Taguchi; K Fujiwara
Journal:  Jpn J Exp Med       Date:  1979-12

6.  Virulence and persistence of three prototype strains of mumps virus in newborn hamsters.

Authors:  J S Wolinsky; W G Stroop
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

7.  Synthesis of mumps virus polypeptides in infected Vero cells.

Authors:  G Herrler; R W Compans
Journal:  Virology       Date:  1982-06       Impact factor: 3.616

8.  Mumps virus replication in human lymphoid cell lines and in peripheral blood lymphocytes: preference for T cells.

Authors:  B Fleischer; H W Kreth
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

9.  Relation of interferon production to the limited replication of Newcastle disease virus in L cells.

Authors:  Y Nagai; Y Ito; M Hamaguchi; T Yoshida; T Matsumoto
Journal:  J Gen Virol       Date:  1981-07       Impact factor: 3.891

10.  Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes.

Authors:  J L Sullivan; D W Barry; S J Lucas; P Albrecht
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

View more
  3 in total

1.  Effects of antibodies and interferon on mumps virus persistently infected L929 cells. Generation of variant viruses in the cells during incubation with monoclonal antibodies and interferon.

Authors:  Y Ito; M Tsurudome; M Hishiyama
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

2.  Replication of mumps virus in mouse: transient replication in lung and potential of systemic infection.

Authors:  M Tsurudome; A Yamada; M Hishiyama; Y Ito
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  Recombinant mumps virus as a cancer therapeutic agent.

Authors:  Arun Ammayappan; Stephen J Russell; Mark J Federspiel
Journal:  Mol Ther Oncolytics       Date:  2016-08-10       Impact factor: 7.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.